Company intelligence / Profile preview

Primo Center

Taipei City, Taiwan

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Primo obtained authorization from ABX to manufacture and distribute Radelumin ([18F]PSMA-1007) for prostate cancer diagnostics in Taiwan, beginning clinical supply in June 2025. The company is advancing pipeline candidates PB011 and PB012 through clinical trials.

Therapeutic areas: Oncology
Modalities: Radiopharmaceutical
Industry: Biotech

Partnerships

ABX advanced biochemical compounds

Beyond the preview

Go deeper on Primo Center.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Primo Center.

Explore the full profile